micro-community-banner
 
  • Saved

Repatha® (evolocumab) injection 140 mg/mL

Sponsored
 
 
 
 
 
 
 
 
 
0 of 1 minute, 4 secondsVolume 0%

Press shift question mark to access a list of keyboard shortcuts

Keyboard Shortcuts
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
 
 
 
 
 

 
 
 
 
 
 
 
00:16
00:48
01:04
 
 
 
 

Learn how Repatha® Made a Difference for Andy After a Double Bypass

Amgen Inc.

Learn more about the effect of Repatha plus a statin on LDL-C in ASCVD patients like Andy who struggle with high LDL cholesterol.

Expand +

IMPORTANT SAFETY INFORMATION
• Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

• Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

• Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.  

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

• Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

• Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

INDICATIONS
Repatha® is indicated:
• To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease

• As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

Please see full Prescribing Information.

©2024 Amgen Inc. All rights reserved. USA-CCF-82189 03/25

  • Saved

1mo

I go by family history. If their LDL is greater than 180 I start with high dose statin and zetia. If we do not reach goal levels, I would add a PCSK9 drug. If patient does not want an injection, I may try Benpendoic acid. In some patients, aphorisms is needed

  • Saved

1mo
infographic
  • Saved

1mo
Cyclosporin A-loaded dissolving microneedles for dermatitis therapy: Development, characterisation and efficacy in a delayed-type hypersensitivity in vivo model - PubMed

Cyclosporin A-loaded dissolving microneedles for dermatitis therapy: Development, characterisation and efficacy in a delayed-type hypersensitivity in vivo model - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38472726/

Several drugs can be used for treating inflammatory skin pathologies like dermatitis and psoriasis. However, for the management of chronic and long-term cases, topical administration is preferred over oral delivery...

A novel cyclosporin A–loaded lipid vesicle microneedle system enhanced skin delivery, reduced inflammation, and improved histological outcomes in dermatitis models, offering a safe, targeted alternative to corticosteroid-based therapies for chronic inflammatory skin conditions.

  • Saved

1mo
Biomarkers transform endocrine disorder management in the critically ill

Endocrine dysfunction is an under-recognized but significant driver of morbidity and mortality in the critically ill. This review highlights how biomarkers enable earlier detection, diagnosis, and monitoring of life-threatening endocrine crises—such as adrenal insufficiency, thyroid storm, and hyperglycemic emergencies—that may initially present with non-specific symptoms.

Highlights:

• Biomarkers—classified as prognostic, predictive, pharmacodynamic, or exposure-related—help guide both diagnosis and treatment decisions.

• Established markers include TSH for thyroid disease, cortisol for adrenal insufficiency, IGF-1 for growth hormone deficiency, and HbA1c for glycemic status.

• Advantages include earlier, objective detection and individualized therapy; limitations involve sensitivity, clinical validation, and interpretive complexity.

• Emerging tools like extracellular vesicles, serum diiodotyrosine, and neutrophil gelatinase-associated lipocalin (NGAL) may offer precision diagnostics.

• Advances in multiplexed and ultra-sensitive detection platforms are improving accuracy and accelerating clinical adoption.

What sets this study apart:

It synthesizes current and emerging biomarker evidence, positioning these tools to shift critical care endocrinology from reactive to precision-guided, proactive management.

Limitations:

Many novel markers lack large-scale validation. Regulatory hurdles and workflow integration also limit clinical translation in intensive care.

How are you leveraging biomarkers to detect endocrine crises earlier in the ICU? Could multiplex technology help improve diagnostic accuracy and resource utilization in your unit?